Jade Biosciences, Inc.
JBIO
$13.97
-$0.28-1.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 6.44M | 5.39M | 5.23M | 3.36M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 34.98M | 27.40M | 27.78M | 23.38M | |
| Operating Income | -34.98M | -27.40M | -27.78M | -23.38M | |
| Income Before Tax | -31.87M | -25.18M | -32.13M | -38.17M | |
| Income Tax Expenses | 58.00K | -- | -- | -- | |
| Earnings from Continuing Operations | -31.93M | -25.18M | -32.13M | -38.17M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -31.93M | -25.18M | -32.13M | -38.17M | |
| EBIT | -34.98M | -27.40M | -27.78M | -23.38M | |
| EBITDA | -34.97M | -27.39M | -27.78M | -- | |
| EPS Basic | -0.50 | -0.48 | -0.86 | -8.86 | |
| Normalized Basic EPS | -0.37 | -0.40 | -0.57 | -4.14 | |
| EPS Diluted | -0.50 | -0.48 | -0.86 | -8.86 | |
| Normalized Diluted EPS | -0.37 | -0.40 | -0.57 | -4.14 | |
| Average Basic Shares Outstanding | 53.99M | 39.58M | 28.43M | 3.43M | |
| Average Diluted Shares Outstanding | 53.99M | 39.58M | 28.43M | 3.43M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |